Advanced

Vanin-1 T26I polymorphism, hypertension and cardiovascular events in two large urban-based prospective studies in Swedes.

Fava, Cristiano LU ; Montagnana, Martina LU ; Danese, E; Sjögren, Marketa LU ; Almgren, Peter LU ; Engström, Gunnar LU ; Hedblad, Bo LU ; Guidi, G C; Minuz, P and Melander, Olle LU (2011) In Nutrition Metabolism and Cardiovascular Diseases
Abstract
BACKGROUND AND AIMS: Vanin-1 (gene name VNN1) is an enzyme with pantetheinase activity generating the amino-thiol cysteamine which is implicated in the regulation of red-ox status through its effect on glutathione. We tested the hypothesis that the rs2294757 VNN1 T26I polymorphism could affect blood pressure (BP) levels, hypertension prevalence, and risk of incident cardiovascular events. METHODS AND RESULTS: The VNN1 T26I polymorphism was genotyped in 5664 participants of the cardiovascular cohort of the "Malmö Diet and Cancer" (MDC-CVA) study and successively in 17874 participants of the "Malmö Preventive project"(MPP). The incidence of cardiovascular events was monitored for an average of nearly 12 years of follow-up in the MDC-CVA and... (More)
BACKGROUND AND AIMS: Vanin-1 (gene name VNN1) is an enzyme with pantetheinase activity generating the amino-thiol cysteamine which is implicated in the regulation of red-ox status through its effect on glutathione. We tested the hypothesis that the rs2294757 VNN1 T26I polymorphism could affect blood pressure (BP) levels, hypertension prevalence, and risk of incident cardiovascular events. METHODS AND RESULTS: The VNN1 T26I polymorphism was genotyped in 5664 participants of the cardiovascular cohort of the "Malmö Diet and Cancer" (MDC-CVA) study and successively in 17874 participants of the "Malmö Preventive project"(MPP). The incidence of cardiovascular events was monitored for an average of nearly 12 years of follow-up in the MDC-CVA and for 25 years in the MPP. Both before and after adjustment for sex, age and BMI in the MDC-CVA the polymorphism had a mild lowering effect on diastolic BP and hypertension, especially in females. However in MPP no effect on BP phenotypes was detectable. Before and after adjustment for major cardiovascular risk factors, the hazard ratio for incident ischemic stroke and coronary events in the MDC-CVA was not significantly different in carriers of different genotypes. CONCLUSIONS: Our data do not support a major role for the VNN1 T26I variant in determining BP level and incident ischemic events. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Nutrition Metabolism and Cardiovascular Diseases
publisher
Elsevier
external identifiers
  • wos:000314111800013
  • pmid:21550219
  • scopus:84872680271
ISSN
1590-3729
DOI
10.1016/j.numecd.2011.01.012
language
English
LU publication?
yes
id
b312478d-62a4-47e5-8d39-522e70e03e60 (old id 1973075)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/21550219?dopt=Abstract
date added to LUP
2011-06-07 14:46:40
date last changed
2017-01-01 03:42:23
@article{b312478d-62a4-47e5-8d39-522e70e03e60,
  abstract     = {BACKGROUND AND AIMS: Vanin-1 (gene name VNN1) is an enzyme with pantetheinase activity generating the amino-thiol cysteamine which is implicated in the regulation of red-ox status through its effect on glutathione. We tested the hypothesis that the rs2294757 VNN1 T26I polymorphism could affect blood pressure (BP) levels, hypertension prevalence, and risk of incident cardiovascular events. METHODS AND RESULTS: The VNN1 T26I polymorphism was genotyped in 5664 participants of the cardiovascular cohort of the "Malmö Diet and Cancer" (MDC-CVA) study and successively in 17874 participants of the "Malmö Preventive project"(MPP). The incidence of cardiovascular events was monitored for an average of nearly 12 years of follow-up in the MDC-CVA and for 25 years in the MPP. Both before and after adjustment for sex, age and BMI in the MDC-CVA the polymorphism had a mild lowering effect on diastolic BP and hypertension, especially in females. However in MPP no effect on BP phenotypes was detectable. Before and after adjustment for major cardiovascular risk factors, the hazard ratio for incident ischemic stroke and coronary events in the MDC-CVA was not significantly different in carriers of different genotypes. CONCLUSIONS: Our data do not support a major role for the VNN1 T26I variant in determining BP level and incident ischemic events.},
  author       = {Fava, Cristiano and Montagnana, Martina and Danese, E and Sjögren, Marketa and Almgren, Peter and Engström, Gunnar and Hedblad, Bo and Guidi, G C and Minuz, P and Melander, Olle},
  issn         = {1590-3729},
  language     = {eng},
  month        = {05},
  publisher    = {Elsevier},
  series       = {Nutrition Metabolism and Cardiovascular Diseases},
  title        = {Vanin-1 T26I polymorphism, hypertension and cardiovascular events in two large urban-based prospective studies in Swedes.},
  url          = {http://dx.doi.org/10.1016/j.numecd.2011.01.012},
  year         = {2011},
}